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*Consequences of both long-term confinement (“Confinement Stress”) and 
hypobaric hypoxia (“Hypoxic Stress”) on Immunity (“Immune-
Modulation/Suppression”) in the Antarctic CONCORDIA Environment.  
https://ntrs.nasa.gov/search.jsp?R=20120007706 2019-08-30T20:00:27+00:00Z

Environmental Factors Difficult travel in/out 
Extreme isolation, even greater than ISS 
Altitude 3200m (10,500 ft) 
Air pressure 645hPa (mbar) 
12-13 Vol% of O2  
 Lack of CO2 in air 
Higher ionization in air (increases oxidative 
metabolism) 
 
•Relative humidity 3-5% 
•Snowfall ~1cm/yr 
•High winds 
•Elevated UV exposure (summer), UV 
deficiency (winter) 
•Mean winter temperature -60 C (-72 F) 
•Mean summer temperature -30 C (-22 F) 
•Disrupted circadian rhythms.   
chronic hypobaric hypoxia 
Human Factors 
•Isolation, confinement for prolonged 
duration 
•Limited communication capability with 
outside world (more isolated than ISS!) 
•International crew, multiple languages 
•Realistic station lifestyle 
•Sleep/wake cycles disrupted 
•Actual extreme environment 
deployment w/ associated risks (not a 
mission analog!) 
•Winter over crew: 12 
•Summer crew: ~50 






(Latent Viral Reactivation) 






sampling Details NASA Lab
Comprehensive immunophenotype WB (see panel) Immune
Intracellular cytokine profiles (T cell) WB PMA+ION, LPS Immune
T cell function WB CD3/CD28, A+B Immune
Secreted cytokine profiles WB Th1/Th2, Inflam. Immune
Viral DNA - PBMC WB EBV Mcgn
Circulating viral-specific T cells WB EBV, CMV Mcgn
Viral-specific T cell function WB EBV, CMV Mcgn
Viral antibodies titers Plasma Plasma EBV, CMV Mcgn
Viral antibodies titers Plasma Plasma VZV Micro
Plasma stress hormones Plasma Plasma cortisol Mcgn
SALIVA ASSAYS
Saliva stress hormones, Diurnal Dry Saliva Dry Saliva cortisol, DHEA Micro
Viral DNA by PCR Liquid Saliva Liquid Saliva CMV*, EBV, VZV Micro
URINE ASSAYS
Viral DNA by PCR 24hr. URINE 24hr. URINE CMV Micro
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2010/2011 Summer Transition 
n=6 
n=9 
Overwinter Flow Cytometry 
Overwinter Data:  
Phenotype 
L-30 Ear. M2 M4 M6 Late R+60
Granulocytes 52 44* 31* 37* 44* 46* 63
Lymphocytes 40 47* 49* 50* 45 44 32
Monocytes 5.0 5.0 10* 7* 5.0 5.0 3.0
T Cells 67 60* 65 55* 54* 56* 77
B Cells 7 13* 12* 11* 19* 13* 12
NK Cells 6 9 10* 12 5 11* 18
CD4+ T Cells 59 55* 50* 51* 50* 53* 61
CD8+ T Cells 33 32 29 26* 25* 30 27
L-30 Ear. M2 M4 M6 Late R+60
Bulk Memory CD4+ 54 59 56 59 62* 68* 49
Bulk Memory CD8+ 37 59* 41 58* 59* 74* 32
CD8: Naïve/ctx 85 49* 65* 57* 62* 53* 92
CD8: Senescent 12 35* 24* 26* 21 27* 7
CD8: True Naïve 38 35 27 31 35 28 21
Central memory 6 10 5 13 10 13 34
Effector Memory 39 32* 37 33 32* 35 38
Term. Differentiated 17 23 31 22 24* 25 7
L-30 Ear. M2 M4 M6 Late R+60
CD4/CD69 1 6* 1 2 2 2 0
CD8/CD69 2 9* 3 3 3 3 2
CD4/HLA-DR 2 3 3 2 1 1 2
CD8/HLA-DR 3 5* 2 2 1 1 3
NAÏVE 
MEMORY 
2009/10 Summer Transition period – Incidence Rates 
 
(mid-November to mid-January) 
 
•Approx. 50% of summer participants contacted 
infectious disease 
 
•Historically, extremely high incidence rate 
 
•Three periods of epidemic viral infections: 
 
   Period 1:  Flu-like (mid-Nov. to mid-Dec.) 
 
   Period 2:  Rhinoparyngitis (mid-Dec. to early 
Jan.) 
 




-Data from Concordia Station, Chief Medical Officer 
Overwinter Data:  
Secreted Cytokine 
Profiles 
T cells:  CD3+CD28 - 48hr
L-30 Ear. F-M A-M J-J A-S Late R+60
IFNg 74 58 100 104 116 138 59 2
TNFa 20 24 24 13 15 21 9 3
IL-10 6 16 5 8 8 9 3 2
IL-4 0 0 0 0 0 0 0 0
IL-5 4 2 7 8 9 5 3 1
IL-2 32 4 64 33 33 43 12 4
All Leukocytes:  PMA+Ionomycin - 48hr
L-30 Ear. F-M A-M J-J A-S Late R+60
IFNg 287 281 251 247 248 238* 220* 238
TNFa 51 82* 105* 127* 98* 111* 35* 52
IL-10 7 19* 16* 21* 19* 20* 5 5
IL-4 3 5* 4* 5* 5* 6* 2 1
IL-5 15 19 17 19* 18 20 11 4
IL-2 689 701 725 764* 764* 736* 526* 572
Monocytes:  LPS - 48hr
L-30 Ear. F-M A-M J-J A-S Late R+60
IL-12 0 0 0 0 0 0 0 0
TNFa 9 20* 17* 18* 21* 17* 12 33
IL-10 14 27* 43* 37* 37* 42* 6 11
IL-6 432 431 498 494 506 477 232 502
IL-1b 51 95* 50 54 57 39 110 175
IL-8 610 583 529 591 600 577 408 636
Collection Time


















Overwinter Data:  Plasma Cortisol 
Collection Time










































































































































































































Overwinter Data:  Salivary DHEA 
    
    Before In Isolation  After  
    Feb  Mar Apr  May  June  July Aug  Sept  Oct    
G - - - - - - - - - - 
H - NA NA NA NA NA NA NA NA NA 
J - - + + - + + + - - 
K - - - - - - - - - - 
L - - - + - + + + - - 
M - - - - - + + - - - 
N - - + + - - - - - - 
O - - - + + - - - - - 
P - - - - - - - - - - 
J - - - - - - - - - - 
  - -         - - - - 
  - -         - - - - 
 
 
 Overwinter Data:  VZV Reactivation 
Varicella Zoster Virus in Saliva Concordia subjects 
before, during and after isolation.
Sample Collection Time

























In- Isolation After Before 
Overwinter Data:  VZV Reactivation 
Morning VZV
Sample Collection Days

























In- Isolation After Before 
1 Feb (M) Before 
3 Mar (M) Before 
5 Apr (M) Isolation 
7 May (M) Isolation 
9 June (M) Isolation 
11 July (M) Isolation 
13 Aug (M) Isolation 
15 Sept (M) Isolation 
17 Oct (M) After 
19 Post Conc (M) After 
22 MF Baseline After 
Overwinter Data:  VZV Reactivation (AM) 
Evening VZV
Saliva Collection Days




























In- Isolation After Before 
Overwinter Data:  VZV Reactivation (PM) 
    Before In Isolation  After  


















(M)   
G JFV - - - - - + + - - - 
H DM - NA NA NA NA NA NA NA NA NA 
J JMM + - - + + + - + - + 
K CR - - - + - - - - + - 
L GD - + + + - - - - - - 
M AB - - - - - - - - - - 
N LM - + + + + + - + - - 
O KA - - - - - - - - - - 
P AR - + - - - + - - - 0 
J AL* - - - - - - - - - - 
  MF - -         - - - - 
  AC' - -         - - - - 
Overwinter Data:  EBV Reactivation 
EBV in Saliva of Concordia subjects before, during and after isolation
Sample Collection Day

























In- Isolation After Befor
e 
Overwinter Data:  EBV Reactivation 
Questions? 
